Skip to main content
SpringerLink
Log in

Effects of two years of growth hormone (GH) replacement therapy on bone metabolism and mineral density in childhood and adulthood onset GH deficient patients

  • Original Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

The aim of the current study was to evaluate bone metabolism and mass before and after 2 years of GH replacement therapy in adults with childhood or adulthood onset GH deficiency. Thirty-six adults with GH deficiency, 18 with childhood onset, 18 with adulthood onset GH deficiency and 28 sex-, age-, height- and weight-matched healthy subjects entered the study. Biochemical indexes of bone turnover such as serum osteocalcin, serum carboxyterminal telopeptide of type-I procollagen, urinary hydroxyproline/creatinine and deoxypyridinoline/creatinine, of soft tissue formation such as aminoterminal propeptide of type-III and bone mineral density were evaluated. Childhood onset GH deficient patients had significantly decreased bone (osteocalcin: 2.5±1.3 vs 6.6±4.8 mcg/l, p<0.001) and soft tissue formation (aminoterminal propeptide of type III: 273±49 vs 454±23 U/l, p<0.001) indexes and normal bone resorption indexes (serum carboxyterminal telopeptide of type-I procollagen: 105±48 vs 128±28 mcg/l p=NS; urinary hydroxyproline/creatinine: 0.19±0.16 vs 0.28±0.16 mmol/mol, p=NS; urinary deoxypyridinoline/creatinine: 21±10 vs 25±8 mcmol/mol, p=NS) compared to healthy subjects. On the contrary, no significant difference in bone turnover indexes between adulthood onset GH deficient patients and healthy subjects was found. Moreover, significantly decreased bone mineral density at any skeletal site and at whole skeleton was found in GH deficient patients compared to healthy subjects (e.g. femoral neck: 0.74±0.13 vs 0.97±0.11 g/cm2, p<0.001). In addition, a significant reduction of bone mineral density was found in childhood compared to adulthood onset GH deficient patients at any skeletal site, except at femoral neck. After 3–6 months of treatment, both groups of patients had a significant increase in bone turnover and in soft tissue formation. In particular, in childhood onset GH deficient patients after 3 months osteocalcin increased from 2.5±1.3 to 7.9±2.1 mcg/l, p<0.001 aminoterminal propeptide of type-III from 273±49 to 359±15 U/l p<0.001; serum carboxyterminal telopeptide of type-I procollagen from 105±48 to 201±45 mcg/l, p<0.001; urinary hydroxyproline/creatinine from 0.19±0.16 to 0.81±0.17 mmol/mol, p<0.001; urinary deoxypyridinoline/creatinine from 21±10 to 54±20 mcmol/mol, p<0.001; while in adulthood onset GH deficient patients after 6 months osteocalcin increased from 4.2±3.6 to 6.5±1.9 mcg/l, p<0.05; aminoterminal propeptide of type-III from 440±41 to 484±37 U/l, p<0.05; serum carboxyterminal telopeptide of type-I procollagen from 125±40 to 152±22 mcg/l, p<0.05; urinary hydroxyproline/creatinine from 0.24±0.12 to 0.54±0.06 mmol/mol, p<0.001; urinary deoxypyridinoline/creatinine from 23±8 to 42±5 mcmol/mol, p<0.001. No significant difference in bone turnover between pre- and post-treatment period was found after 18-24 months of GH therapy. Conversely, bone mineral density was slightly reduced after 3–6 months of GH therapy, while it was significantly increased after 18–24 months. In fact, femoral neck bone mineral density values significantly rose from 0.74±0.13 g/cm2 to 0.87±0.11 g/cm2 (pre-treatment vs 2 years of GH treatment values). In conclusion, patients with childhood or adulthood onset GH deficiency have osteopenia that can be improved by long-term treatment with GH.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Cuneo R.C., Salomon F., McGauley G.A., Sonksen P.H. The growth hormone deficiency syndrome in adults. Clin. Endocrinol. 1992, 37: 387–397.

    Article  CAS  Google Scholar 

  2. Carrol P.V., Christ E.R., Bengtsson B.A., Carlsson L., Christiansen J.S., Clemmons D., Hintz R., Ho K., Laron Z., Sizonenko P., Sonksen P.H., Tanaka T., Thomer M. Growth hormone deficiency in adulthood and the effect of growth hormone replacement: a review. J. Clin. Endocrinol. Metab. 1998, 83: 382–395.

    Article  Google Scholar 

  3. Wuster C.H.R., Slenczka E., Ziegler R. Erhohte Pravalenz von Osteoporose und Arteriosklerose bei konventionell Substituierter Hypophysenvorderlappeninsuffizienz: befard einer zusatzlichen Wachstumshormonsubstitution? Klin. Wochensch. 1991, 69: 769–773.

    Article  CAS  Google Scholar 

  4. Sartorio A., Ortolani S., Conti A., Cherubini R., Galbiati E., Faglia G. Effects of recombinant growth hormone (GH) treatment on bone mineral density and body composition in adults with childhood onset growth hormone deficiency. J. Endocrinol. Invest. 1996, 19: 524–529.

    CAS  PubMed  Google Scholar 

  5. Kaufmann J.M., Taelman P., Vermeulen A., Vandeweghe M. Bone mineral status in growth hormone-deficient males with isolated and multiple pituitary deficiencies of childhood onset. Clin. Endocrinol. Metab. 1992, 74: 118–123.

    Google Scholar 

  6. Bravenboer N., Holzmann P., De Boer H., Blok G.J., Lips P. Histomorphometric analysis of bone mass and bone metabolism in growth hormone deficient adult men. Bone 1996, 8: 551–557.

    Article  Google Scholar 

  7. Finkenstedt G., Gasser R.W., Hofle G., Watfah C., Fridrich L. Effects of growth hormone (GH) replacement on bone metabolism and mineral density in adult onset of GH deficiency: results of a double-bone placebocontrolled study with open follow-up. Eur. J. Endocrinol. 1997, 136: 282–289.

    Article  CAS  PubMed  Google Scholar 

  8. Holmes S.J., Shalet S.M. Adult growth hormone deficiency and bone mass. Horm. Res. 1996, 45: 69–71.

    Article  CAS  PubMed  Google Scholar 

  9. Balducci L., Toscano V., Pasquino A.M., Mangiantini A., Municchi G., Armenise P., Terracina S., Prossomariti G., Boscherini B. Bone turnover and bone mineral density in young adult patients with panhypopituitarism before and after long-term growth hormone therapy. Eur. J. Endocrinol. 1995, 132: 42–46.

    Article  CAS  PubMed  Google Scholar 

  10. Amato G., Izzo G., La Montagna G., Bellastella A. Low dose recombinant human growth hormone normalizes bone metabolism and cortical bone density and improves trabecular bone density in growth hormone deficient adults without causing adverse effects. Clin. Endocrinol. 1996, 45: 27–32.

    Article  CAS  Google Scholar 

  11. Stiegler C., Leb G. One year of replacement therapy in adults with growth hormone deficiency. Endocrinol. Metab. 1994, 1: 37–39.

    Google Scholar 

  12. Hansen T.B., Brixen K., Vahl N., Jorgensen J.O.L., Christiansen J.S., Mosekilde L., Hagen C. Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium homeostasis, and bone metabolism in adults with acquired GH deficiency: a double blind, randomized, placebocontrolled study. Clin. Endocrinol. Metab. 1996, 81: 3352–3356.

    CAS  Google Scholar 

  13. Holmes S.J., Whitehouse R.W., Swindell R., Economou G., Adams J.E., Shalet S.M. Effect of growth hormone replacement therapy on bone mass in adults with adult onset growth hormone deficiency. Clin. Endocrinol. 1995, 42: 627–633.

    Article  CAS  Google Scholar 

  14. Rosen T., Johannsson G., Hallgren P., Caidhal K., Bosaeus I., Bengtsson B.A. Beneficial effects of 12 months replacement therapy with recombinant human growth hormone to growth hormone deficient adults. Endocrinol. Metab. 1994, 1: 55–66.

    CAS  Google Scholar 

  15. Bollerslev J., Moller J., Thomas S., Djoseland O., Christiansen J.S. Dose-dependent effects of recombinant human growth hormone on biochemical markers of bone and collagen metabolism in adult growth hormone deficiency. Eur. J. Endocrinol. 1996, 135: 666–671.

    Article  CAS  PubMed  Google Scholar 

  16. Johannsson G., Bengtsson B-A. Growth hormone and the acquisition of bone mass. Horm. Res. 1997, 48: 72.

    Article  PubMed  Google Scholar 

  17. Beshyah S.A., Thomas E., Kyd P., Sharp P., Fairney A., Johnston D.G. The effect of growth hormone replacement therapy in hypopituitary adults on calcium and bone metabolism. Clin. Endocrinol. 1994, 40: 383–391.

    Article  CAS  Google Scholar 

  18. Vandeweghe M., Taelman P., Kaufmann J.M. Short and long-term effects of growth hormone treatment on bone turnover and bone mineral content in adult growth hormone-deficient males. Clin. Endocrinol. 1993, 39: 409–415.

    Article  CAS  Google Scholar 

  19. Rahim A., Holmes S.J., Adams J. E., Shalet S.M. Long-term change in bone mineral density of adult with adult onset growth hormone (GH) deficiency in response to short or long-term GH replacement therapy. Clin. Endocrinol. 1998, 48: 463–489.

    Article  CAS  Google Scholar 

  20. Longobardi S., Merola B., Pivonello R., Di Rella F., Di Somma C., Colao A., Ghigo E., Camanni F., Lombardi G. Reevaluation of growth hormone (GH) secretion in 69 adults diagnosed as GH-deficient patients during childhood. Clin. Endocrinol. Metab. 1996, 81: 1244–1247.

    CAS  Google Scholar 

  21. Eyre D.R. Collagen cross-linking aminoacids. In: Cunningham L.W. (Ed.), Methods in Enzimology. Academy Press, New York, 1987, vol. 44, p. 115.

    Google Scholar 

  22. Glastre C., Braillon P., David L., Cochat P., Meunier P.J., Delmas P.D. Measurement of bone mineral content in the lumbar spine by dual energy x-ray absorptiometry in normal children: correlations with growth parameters. Clin. Endocrinol. Metab. 1990, 70: 1330–1333.

    Article  CAS  Google Scholar 

  23. Ott S.M. Attainment of peak bone mass. Clin. Endocrinol. Metab. 1990, 71: 1082A–1082C.

    Article  CAS  Google Scholar 

  24. Degerbald M., Bengtsson B.A., Bramnert M., Johnell O., Manhem P., Rosen T., Thoren M. Reduced bone mineral density in adults with growth hormone (GH) deficiency: increased bone turnover during 12 months of GH substitution therapy. Eur. J. Endocrinol. 1995, 133: 180–188.

    Article  Google Scholar 

  25. Shore R.M., Chesney R.W., Mazess R.B., Rose P.G., Bargman G.J. Bone mineral status in growth hormone deficiency. J. Pedriatr. 1980, 96: 393–396.

    Article  CAS  Google Scholar 

  26. O’Halloran D.J., Tsatsoulis A., Whitehouse R.W., Holmes S.J., Adams J.E., Shalet S.M. Increased bone density after recombinant human growth hormone (GH) therapy in adults with isolated GH deficiency. Clin. Endocrinol. Metab. 1993, 76: 1344–1348.

    Google Scholar 

  27. Binnerts A., Swart G.R., Wilson J.H.P., Hoogerbrugge N., Pols H.A.P., Birkenhager J.C., Lamberts S.W.J. The effect of growth hormone administration in growth hormone deficient adults on bone, protein, carbohydrate and lipid homeostasis, as well as on body composition. Clin. Endocrinol. 1992, 37: 79–87.

    Article  CAS  Google Scholar 

  28. Whitehead H.M., Boreham C., Mcllrath M.N., Sheridan B., Kennedy L., Atkinson A.B., Hadden D.R. Growth hormone treatment of adults with growth hormone deficiency: results of a 13-month placebo controlled cross-over study. Clin. Endocrinol. 1992, 36: 45–52.

    Article  CAS  Google Scholar 

  29. Johannsson G., Rosen T., Bosaeus I., Sjostrom L., Bengtsson B.A. Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency. Clin. Endocrinol. 1996, 81: 2865–2873.

    CAS  Google Scholar 

  30. De Boer H., Blok G.J., Van der Veen E.A. Clinical aspects of growth hormone deficiency in adults. Endocr. Rev. 1996, 16: 63–86.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Molecular and Clinical Endocrinology and Oncology, Chair of Nuclear Medicine, “Federico II” University, Via Catena 7, 80126, Napoli, Italy

    S. Longobardi M.D., F. Di Rella, R. Pivonello, C. Di Somma, A. Colao, B. Merola & G. Lombardi

  2. Institute of Radiological Science, Chair of Nuclear Medicine, “Federico II” University, Napoli, Italy

    M. Klain & L. Maurelli

  3. Department of Internal Medicine, “Federico II” University, Napoli, Italy

    R. Scarpa

Authors
  1. S. Longobardi M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Di Rella
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Pivonello
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Di Somma
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Klain
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. L. Maurelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R. Scarpa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. Colao
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. B. Merola
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. G. Lombardi
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Longobardi, S., Di Rella, F., Pivonello, R. et al. Effects of two years of growth hormone (GH) replacement therapy on bone metabolism and mineral density in childhood and adulthood onset GH deficient patients. J Endocrinol Invest 22, 333–339 (1999). https://doi.org/10.1007/BF03343570

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03343570

Key-words

Search

Navigation